Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome + lobaplatin
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Irinotecan liposome + lobaplatin is an investigational combination chemotherapy regimen primarily being evaluated for the treatment of small cell lung cancer (SCLC), including cases that have progressed after first-line therapy. Irinotecan liposome (Onivyde) is a nanoparticle-encapsulated formulation of irinotecan, which is converted to its active metabolite SN-38 to inhibit DNA topoisomerase I, leading to lethal DNA damage. Lobaplatin is a third-generation platinum derivative that induces DNA inter-strand and intra-strand cross-links, effectively inhibiting DNA synthesis and transcription. This combination is designed to enhance therapeutic efficacy and overcome drug resistance in SCLC through complementary mechanisms of DNA damage. Clinical development is notably supported by institutions such as The Fourth Affiliated Hospital of Nanjing Medical University.
- Brand names
- Onivyde
- Other names
- irinotecan liposome + lobaplatin
02
Targets
TOP1 (DNA Topoisomerase I)TOP1MT (Mitochondrial topoisomerase I)
Beyond the preview
Go deeper on irinotecan liposome + lobaplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome + lobaplatin.